Table 2 Estimates used to determine parameters for the decision tree model*
From: Cost-effectiveness analysis of malaria chemoprophylaxis for travellers to West-Africa
Definition of probabilities | Estimates (likliest, 95% CI) | Date of data | References |
|---|---|---|---|
Current probability of recourse to malaria chemoprophylaxis in current situation of no reimbursement | 0.687/0.55/0.824 | 2002-2003 | |
Probability of recourse to malaria chemoprophylaxis in the 80% reimbursement strategy | 0.865/0.806/0.925 | - | |
Probability of recourse to mefloquine | 0.554 | 2007 | Personal evaluation at the STI1 |
Probability of recourse to atovaquone/proguanil | 0.407 | 2007 | Personal evaluation at the STI1 |
Probability of recourse to doxycycline | 0.039 | 2007 | Personal evaluation at the STI1 |
Probability of adverse events due to mefloquine leading to withdrawal | 0.04 (0.01-0.08) | 1998-2001 | [9] |
Probability of adverse events due to atovaquone/proguanil leading to withdrawal | 0.02 (0.00-0.04) | 1998-2001 | [9] |
Probability of adverse events due to doxycyline leading to withdrawal | 0.03 (0.00-0.06) | 1998-2001 | [9] |
Probability of severe adverse events due to mefloquine without withdrawal | 0.11 (0.06-0.15) | 1998-2001 | [9] |
Probability of severe adverse events due to atovaquone/proguanil without withdrawal | 0.07 (0.02-0.11) | 1998-2001 | [9] |
Probability of severe adverse events due to doxycyline without withdrawal | 0.06 (0.02-0.10) | 1998-2001 | [9] |
Probability of contracting malaria without malaria chemoprophylaxis | 0.0242 (Varied ± 30%: 0.017 - 0.0314) | - | [18] |
Prophylactic effectiveness of mefloquine | 0.945 (0.84-0.981) | 1993-1995 | [19] |
Prophylactic effectiveness of atovaquone/proguanil | 0.958 (0.915-0.975) | Metaanalysis 2007 | [20] |
Prophylactic effectiveness of doxycyline | 0.926 (0799-0.975) | 1995 | [21] |
Rate of hospitalisation of the imported malaria cases in Switzerland | 0.63 | 2003-2006 | Personal evaluation with data from FOPH2 and SFSO3 |
Medical cost variables | Estimates (likliest) | Date of data | References |
Direct cost of mefloquine (Mephaquin®) for two weeks in 80% reimbursement strategy | € 17.77 | 2008 | [17] |
Cost to treat adverse events | € 37.59 | 2008 | Personal evaluation with TARMED4 and Swiss drug compendium[17] |
Direct cost of hospitalisation due to a malaria case | € 4763 | 2004-2005 | Personal communication (SFSO) |
Direct cost of ambulant treatment due to a malaria case | € 368 | 2008 | Personal communication (STI) |
Average indirect cost of sick leave due to a malaria case | € 2123 | 1996-2004 | Personal communication (SUVA5) |